Seven patients with normal specialized conduction system and three patients with the Wolff-Parkinson-White (WPW) syndrome were studied using programmed stimulation of the feart before and after the administration of intravenous disopyramide. The principal effect of this drug was to prolong the effective refractory period of the atria and ventricles, and to prolong the effective refractory period of the anomalous pathway in the WPW syndrome. In addition, it prolonged the conduction time in the anomalous pathway in the WPW syndrome. These findings suggest that disopyramide would be a useful and safe drug in the management of certain atrial and ventricular arrhythmias and in the management of the Wolff-Parkinson-White syndrome with atrial fibrillation.
Disopyramide (Rythmodan) is an antiarrhythmic agent which has been found valuable in the management of extrasystoles and tachycardias of both supraventricular and ventricular origin (Vismara, Mason, and Amsterdam, I974; Katz et al., I963; Desruelles et al., I967) . Using techniques of intracardiac recordings and programmed electrical stimulation of the heart, we have studied the effects of disopyramide on the electrophysiological properties of the specialized conduction system in man, and in addition its effect on the anomalous atrioventricular pathway in the Wolff-Parkinson-White (WPW) syndrome.
Patients and methods
Ten patients, 5 male and 5 female, were studied and their clinical details are shown on Table i . Case I underwent an electrophysiological study while undergoing routine cardiac catheterization for a ventricular septal defect. Cases 2, 4, 5, and 6 were undergoing routine electrophysiological study for the investigation of recurrent rapid palpitations. In each patient the resting electrocardiogram was normal and no tachycardia could be initiated during the study which in each patient demonstrated a normal conduction system. Cases 3 and 7 underwent electrophysiological study for the further investigation of previously documented ventricular Received 17 March 1975. tachycardia: in both patients the resting electrocardiograms were normal. Cases 8, 9, and io had the WPW syndrome with recurrent bouts of supraventricular tachycardia; the resting electrocardiogram in each patient showed the typical features of the WPW syndrome. Informed consent was obtained from each patient or from the parents of Cases I, 8, and 9. All patients underwent the electrophysiological study in the postabsorptive non-sedated state. No patient was receiving drug medication at the time of the study. Three bipolar electrode catheters were introduced percutaneously via one or both femoral veins. One catheter was positioned high in the right atrium to record a high right atrial electrogram. One catheter was positioned across the tricuspid valve to record a His bundle electrogram using the technique described by Scherlag et al. (1969) . The His bundle electrogram was recorded at a filter setting of 40 to 50 c/s. The intracardiac recordings were made simultaneously with leads I, III, Vi, and V6 of the surface electrocardiogram. All recordings were made on an 8-channel Elema Mingograph 8i at a paper speed of ioo mm/s. The third catheter was positioned in either the right atrium or ventricle for atrial or ventricular pacing and inducing single or double atrial or ventricular prem-ature beats. In Cases 8 and io an additional catheter electrode was positioned in the coronary sinus to record left atrial activity.
A Devices 42701 stimulator was used for atrial and 'Devices Instruments Ltd., Welwyn Garden City, Hertfordshire. Latency time is the time from the pacing stimulus artefact to the earliest onset of atrial or ventricular activation. All measurements were made in milliseconds. The above measurements were made before the administration of disopyramide and were repeated at 2, 5, I0, I5, 20, and 30 minutes after the intravenous administration of disopyramide in a dose of 2 mg/kg body weight. In the patients with the WPW syndrome the tachycardia was initiated before the administration of the drug in each case in order to study the effect of the drug on the reciprocal circuit during tachycardia.
Only the maximal changes in the conduction times or refractory periods after disopyramide administration are reported in the Tables and in each patient this occurred between 2 and 5 minutes after administration. In most patients all the measurements had returned to near control values after 30 minutes.
The conduction times before and after disopyramide are given at the same basic Stl-St2 intervals to avoid changes in conduction caused by changes in cycle length. For the same reason refractory periods were recorded before and after disopyramide using the same basic cycle during premature stimulation. Results No patient suffered any side effect from the administration of disopyramide. Patients with normal conduction system The functional refractory period of the atrioventricular node was minimally changed in 2 patients only.
The effective refractory period of the atrioventricular node could not be measured either before or after disopyramide in Case i owing to the effective refractory period of the atria being longer than that of the atrioventricular node. In Cases 3 and 5 the effective refractory period of the atrium was increased by disopyramide to such an extent that it became longer than that of the atrioventricular node and as such the effective refractory period of the atrioventricular node could not be measured in these 2 patients after disopyramide administration. In the remaining patients the effective refractory period of the atrioventricular node was only minimally affected in that it increased by 5 ms in one patient, by 20 ms in another, and was unchanged in 2 patients.
The effective refractory period of the ventricle was consistently increased by between io and 50 ms in all 7 patients after the administration of disopyramide.
During refractory period measurements it was found that after disopyramide administration the latency time increased in some patients, particularly during premature stimulation. Patients with WPW syndrome The refractory period measurements in Cases i to 7 showed that the main effect of disopyramide was to increase the effective refractory period of the atria, in one patient by as much as II5 ms. Similar results were also obtained by Josephson et al. (1973) , though the prolongation of atrial refractory period in their cases was not so striking.
In this study a consistent prolongation of the effective refractory period of the ventricle was found but was not so obvious as the prolongation of atrial refractory period.
The effect of disopyramide on the effective refractory period of the atrioventricular node was small and could not be measured in 3 patients as the effective refractory period of the atria was prolonged in excess of that of the atrioventricular node.
This predominant effect of disopyramide on the atria and ventricles may explain its apparent effectiveness in the treatment of atrial and ventricular extrasystoles (Vismara et al., I974; Katz et al., I963; Desruelles et al., I967). Supraventricular tachycardias which are caused by a re-entry or reciprocal mechanism within the atria or within the atrioventricular node may be initiated by atrial extrasystoles; the effect of disopyramide on the atria and its reported effectiveness in the suppression of atrial extrasystoles should, therefore, make this a valuable drug in the prevention of paroxysms of supraventricular tachycardia caused by the above two mechanisms. In terms of termination rather than prevention of a supraventricular tachycardia, if the tachycardia is caused by a re-entry mechanism within the atria the prolongation of the effective refractory period of the atria by disopyramide should make this a useful drug for the termination of such tachycardias. However, because of disopyramide's minimal effect upon the atrioventricular node it would not be expected to be so effective in terminating a supraventricular tachycardia caused by an intra-atrioventricular nodal reciprocal mechanism.
The prolongation of atrial effective refractory period by disopyramide may well explain the mechanism by which this drug is reported to reduce the incidence of recurrence of atrial fibrillation after successful electroconversion to sinus rhythm (Hartel, Louhija, and Konttinen, I974).
The prolongation of the effective refractory period of the ventricles may explain why disopyramide is effective in the suppression of ventricular ectopics. It is now well recognized that ventricular tachycardia in some patients may well be caused by a reentry or reciprocal mechanism (Wellens, Schuilenburg, and Durrer, I972; Spurrell, Sowton, and Deuchar, I973). (Roy, Spurrell, and Sowton, I974) are useful drugs for their blocking action on the antegrade pathway of the tachycardia. In this study disopyramide has been shown to delay conduction and prolong the effective refractory period of the anomalous bypass in the WPW syndrome and so should be of value in the termination of the circus movement tachycardia, and indeed the tachycardia was terminated in Cases 9 and io (Fig.) . In these two patients the retrograde conduction time in the accessory pathway lengthened after disopyramide but the antegrade conduction time in the atrioventricular node His pathway shortened. In Case IO this shortening of antegrade conduction time was in fact sufficient to increase the rate of the tachycardia (the cycle length was reduced from 400 to 350 ms). The reason for this shortening of antegrade conduction is not known as the studies in Cases I to 7 did not suggest such an effect on the atrioventricular node His pathway. It may be that during reciprocal tachycardia the prolongation of conduction time in the retrograde part of the circuit was sufficient to allow longer for the atrioventricular nodal His pathway to recover and result in a faster atrioventricular nodal conduction time. In Case 8, however, disopyramide prolonged both retrograde and antegrade conduction times and it can only be assumed that this must have resulted from a direct effect by the drug on the atrioventricular node (the H-V time was unchanged). This finding is a little bizarre as in Cases I tO 7 no such prolongation of atrioventricular nodal conduction by disopyramide was observed. The tachycardia was not terminated by the drug in Case 8 and this may be because disopyramide had prolonged the conduction times in both parts of the re-entry circuit, thereby allowing a balance of conduction time and refractoriness to remain between antegrade conduction in the atrioventricular node His pathway and retrograde conduction in the anomalous pathway such that the tachycardia could continue but with a longer cycle length.
The other type of tachycardia associated with the WPW syndrome is atrial fibrillation or atrial flutter. In the absence of an anomalous pathway the ventricles are protected from rapid activation during atrial fibrillation by the development of physiological block within the atrioventricular node. However, in the WPW syndrome ventricular activation may occur by way of the anomalous bypass and the frequency will depend upon the effective refractory period of the anomalous bypass. If the refractory period of the accessory pathway is too short, then there is a risk of ventricular fibrillation caused by activation of the ventricles at high frequency via the anomalous pathway from the fibrillating atria. Therefore, any drug that shortens the refractory period of the anomalous pathway will increase the risk of ventricular fibrillation when the refractory period of the bypass tract is already short. This situation has been described by Dreifus et al. (I97I) in a patient with the WPW syndrome and atrial fibrillation, in whom recurrent bouts of ventricular fibrillation appeared to be related to the administration of digoxin. There is evidence that in some cases of the WPW syndrome digoxin shortens the refractory period of the anomalous pathway (Wellens and Durrer, I973) and this could explain the above phenomenon. It is, therefore, important to assess the electrophysiological properties of a drug whose use is going to be considered in the WPW syndrome. In this paper disopyramide has been shown to prolong the effective refractory period of the anomalous bypass and so should be a safe and useful drug to administer to patients with the WPW syndrome and atrial fibrillation. In this context, therefore, administration of disopyramide would be expected to reduce the ventricular rate during atrial fibrillation. 
